Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

NASDAQ:AMGN

Amgen Inc. (AMGN)

336.13
-1.47 (0.44%)
as of Jun 18, 2026, 10:19:00 pm Market Open.
47 watching
0
TOP PICK
Almost any large cap pharma stock in North America is coming out of a 10 and 12 year bases and they have lots of upside. This one has virtually no competition coming from generics. Very strong franchises in cancer and anaemia. About an 8% free cash flow yield.
PAST TOP PICK
(A Top Pick Apr 21/09. Up 16.99%.) Sold out at a substantially higher price and made at least 50%.
PAST TOP PICK
(A Top Pick Apr 21/09. Up 11.51%.) Sold his holdings
PAST TOP PICK
(A Top Pick April 21/09. Up 10.31%.) Either came close to his model price or he found something of more value so he sold his holdings.
PAST TOP PICK
(A Top Pick April 21/09. Up 29.83%.) Sold his holdings at a good gain.
BUY ON WEAKNESS
Largest biotech stock in the US. He prefers biotech to pharma. This one is quite a reasonable company but thinks the markets are a little overdone at these levels. You won't go too far wrong but try to get it in the mid-to low $50's.
BUY
Bio Pharma. Just came out with some promising test results on a bone cancer drug. Trading at about 15X earnings, which is very reasonable. Decent dividend.
COMMENT
Very interested in the biotech space. This one has been sitting unnoticed for a little while. Even more interesting would be the Biotech HLDRs (BBH-N). (See comments under BBH-N).
TOP PICK
Model $59.79. Drugs have been showing up. Get it before the numbers come in. Market selling off in light of expected earnings.
DON'T BUY
Stocks that under perform in a bull market tend to under perform more in a bear market. They have a decelerating growth rate. Expect there will be sales reduction over the next year.
COMMENT
From a technical perspective, he would look for it to carve out a double bottom, or a higher low.
DON'T BUY
Can't get enthused about the pharmaceutical markets. The amount of government action, the pressures, the lawsuits, etc. makes it a high-risk area.
SELL
There are concerns that the growth level in the business indicates there has been a dissatisfaction and lack of interest in pharmaceutical and drug companies. Below the 200 day moving average.
BUY
One of the great pharmaceutical stories. Fabulous company. The whole industry has been lackluster for last 2/3 years. This has been driven by patent litigation and lawsuits. Probably a reasonable price right now.
BUY
The biotech sector has done well this year. This stock has held up well during the market correction. Looks like it has started into a longer climb higher. Because of the current market risk, you have to pick your entries.
Showing 76 to 90 of 124 entries